NRD
ANIP icon

Nebula Research & Development’s ANI Pharmaceuticals ANIP Stock Holding History

Nebula Research & Development’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,931
Closed -$330K – 951
2025
Q1 		$330K Sell
4,931
-7,125
-59% -$426K 0.03% 730
2024
Q4 		$666K Sell
12,056
-788
-6% -$45.2K 0.08% 446
2024
Q3 		$766K Buy
12,844
+7,211
+128% +$440K 0.09% 407
2024
Q2 		$359K Sell
5,633
-5,006
-47% -$325K 0.06% 535
2024
Q1 		$735K Buy
+10,639
New +$642K 0.16% 228

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.66B AUM 27.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Nebula Research & Development's ANIP Position: Q2 2025 in Review

Nebula Research & Development sold out of ANI Pharmaceuticals (ANIP) in Q2 2025, closing a stake of 4,931 shares — an estimated $330K sold.

Nebula Research & Development first reported a position in ANIP in Q1 2024 and held it in 5 quarters. The position peaked at $766K in Q3 2024. 232 funds tracked by Wall St. Rank hold ANIP as of Q2 2025.

  • Nebula Research & Development reported no remaining ANI Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Nebula Research & Development sold 4,931 ANI Pharmaceuticals shares in Q2 2025, an estimated $330K.
  • Nebula Research & Development first reported a position in ANI Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Nebula Research & Development's ANI Pharmaceuticals position peaked at $766K in Q3 2024.
  • 232 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2025.

Based on Nebula Research & Development's 13F filing for Q2 2025, filed 14 Aug 2025.